Literature DB >> 19246508

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.

Chao-Hung Kuo1, Huang-Ming Hu, Fu-Chen Kuo, Ping-I Hsu, Angela Chen, Fang-Jung Yu, Pei-Yun Tsai, I-Chen Wu, Sheng-Wen Wang, Chia-Jung Li, Bi-Chuang Weng, Lin-Li Chang, Chang-Ming Jan, Wen-Ming Wang, Deng-Chyang Wu.   

Abstract

OBJECTIVES: This prospective study was designed to determine the efficacy of a levofloxacin-based rescue therapy for Helicobacter pylori infection after failure of standard triple therapies. We also surveyed the predictors of this rescue therapy. PATIENTS AND METHODS: From June 2005 to March 2007, 1036 patients infected with H. pylori received standard triple regimens (proton pump inhibitor, clarithromycin and amoxicillin). H. pylori eradication was achieved in 855 (82.5%) subjects. One hundred and sixty-six eradication-failure patients were enrolled and randomly assigned to receive a 7 day eradication therapy with esomeprazole, bismuth subcitrate, tetracycline and metronidazole (EBTM) or esomeprazole, amoxicillin and levofloxacin (EAL). Follow-up endoscopy was done 16 weeks later to assess the treatment response. Patients' response, CYP2C19 genotypes and antibiotic resistances were also examined.
RESULTS: Intention-to-treat analysis revealed that both groups showed similar eradication rates [EBTM 63.9%; 95% confidence interval (CI): 53.6-74.2 and EAL 69.9%; 95% CI: 60.1-79.7] (P = 0.89). Per-protocol results were EBTM = 84.1% (95% CI: 75.1-93.1) and EAL = 75.3% (95% CI: 65.8-84.8) (P = 0.82). Both regimens had similar compliance (P = 0.32), but the EBTM group had more adverse events (P = 0.27). Logistic regression analysis showed that poor compliance, CYP2C19 homozygous extensive metabolizer genotype and levofloxacin resistance were important predictors for eradication failure.
CONCLUSIONS: The EAL regimen can achieve an efficacy similar to that of the standard EBTM therapy. It may be very useful in countries where bismuth salts are not available. Compliance, CYP2C19 genotype and resistances to antibiotics may influence the outcome of levofloxacin-based rescue therapy. It seems advisable to reserve levofloxacin for rescue treatment to avoid an increase in the resistance phenomenon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246508     DOI: 10.1093/jac/dkp034

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  35 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

3.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

4.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

5.  Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori.

Authors:  Adnan Khan; Amber Farooqui; Hamid Manzoor; Syed Shakeel Akhtar; Muhammad Saeed Quraishy; Shahana Urooj Kazmi
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 6.  A new look at anti-Helicobacter pylori therapy.

Authors:  Seng-Kee Chuah; Feng-Woei Tsay; Ping-I Hsu; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

7.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

8.  Response to metronidazole and oxidative stress is mediated through homeostatic regulator HsrA (HP1043) in Helicobacter pylori.

Authors:  Igor N Olekhnovich; Serhiy Vitko; Meaghan Valliere; Paul S Hoffman
Journal:  J Bacteriol       Date:  2013-12-02       Impact factor: 3.490

Review 9.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

10.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.